FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966403265> ?p ?o ?g. }

• W1966403265 abstract "Background: Numerous studies have examined prognostic factors for survival in breast cancer patients (pts), but few have focused on long-term survival among pts with HER2+ MBC receiving HER2-targeted therapy. In this study we sought to evaluate the clinical characteristics and predictive factors of long-term survival in this group of pts. Methods: All pts with HER2+ MBC treated with HER2-directed therapy at MD Anderson Cancer Center were identified by retrospective review of the Institutional Breast Medical Oncology database. HER2 status was determined by IHC or FISH. Patient characteristics were analyzed using descriptive statistics. Overall survival (OS) was measured from the date of diagnosis of the first distant metastasis to the date of death or last contact. Pts were grouped according to OS and categorized as long term-survivors (LTS, OS ≥5 years), or non-long term survivors (non-LTS, OS Results: We identified 1603 pts diagnosed with HER2+ MBC between 1994 and 2012 and treated with HER2-targeted therapy. A total of 154 (14.5%) pts were categorized as LTS (median follow-up 80 months, median OS 92.2 months); in this subgroup we identified 10 pts that survived ≥10 years. There were 909 (85.5%) not-LTS (median follow-up 20 months, median OS 27.6 months). Among LTS, 67.5% of the pts were younger than 50 years old; 63.4% had HR-positive tumors and initial stage at the time of diagnosis was I in 11.9%, II in 39.9%, III in 16.3% and stage IV de novo in 32% of the pts. 5-year survival estimates demonstrated differences according to age (31% in patients ≤50 years vs. 25% in patients >50, p = 0.005); stage at diagnosis (25% for stage I-III vs. 36% for stage IV de novo, p Conclusions: Some patients with HER2+positive MBC have an excellent outcome, particularly younger pts with HR-positive tumors, low burden of disease and non-visceral metastases in which multidisciplinary treatment is favored. In the era of HER2-targeted therapies, 14.5% of the patients are long-term survivors. To our knowledge this is the largest series identifying the characteristics of this group of patients. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-02." @default.
• W1966403265 created "2016-06-24" @default.
• W1966403265 creator A5015574967 @default.
• W1966403265 creator A5027688628 @default.
• W1966403265 creator A5033385081 @default.
• W1966403265 creator A5048211837 @default.
• W1966403265 creator A5059063695 @default.
• W1966403265 creator A5080832682 @default.
• W1966403265 creator A5083897606 @default.
• W1966403265 creator A5087724207 @default.
• W1966403265 date "2012-12-15" @default.
• W1966403265 modified "2023-09-25" @default.
• W1966403265 title "Abstract P5-20-02: Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC)." @default.
• W1966403265 doi "https://doi.org/10.1158/0008-5472.sabcs12-p5-20-02" @default.
• W1966403265 hasPublicationYear "2012" @default.
• W1966403265 type Work @default.
• W1966403265 sameAs 1966403265 @default.
• W1966403265 citedByCount "0" @default.
• W1966403265 crossrefType "proceedings-article" @default.
• W1966403265 hasAuthorship W1966403265A5015574967 @default.
• W1966403265 hasAuthorship W1966403265A5027688628 @default.
• W1966403265 hasAuthorship W1966403265A5033385081 @default.
• W1966403265 hasAuthorship W1966403265A5048211837 @default.
• W1966403265 hasAuthorship W1966403265A5059063695 @default.
• W1966403265 hasAuthorship W1966403265A5080832682 @default.
• W1966403265 hasAuthorship W1966403265A5083897606 @default.
• W1966403265 hasAuthorship W1966403265A5087724207 @default.
• W1966403265 hasConcept C121608353 @default.
• W1966403265 hasConcept C126322002 @default.
• W1966403265 hasConcept C143998085 @default.
• W1966403265 hasConcept C146357865 @default.
• W1966403265 hasConcept C151730666 @default.
• W1966403265 hasConcept C167135981 @default.
• W1966403265 hasConcept C2775930923 @default.
• W1966403265 hasConcept C530470458 @default.
• W1966403265 hasConcept C71924100 @default.
• W1966403265 hasConcept C72563966 @default.
• W1966403265 hasConcept C86803240 @default.
• W1966403265 hasConceptScore W1966403265C121608353 @default.
• W1966403265 hasConceptScore W1966403265C126322002 @default.
• W1966403265 hasConceptScore W1966403265C143998085 @default.
• W1966403265 hasConceptScore W1966403265C146357865 @default.
• W1966403265 hasConceptScore W1966403265C151730666 @default.
• W1966403265 hasConceptScore W1966403265C167135981 @default.
• W1966403265 hasConceptScore W1966403265C2775930923 @default.
• W1966403265 hasConceptScore W1966403265C530470458 @default.
• W1966403265 hasConceptScore W1966403265C71924100 @default.
• W1966403265 hasConceptScore W1966403265C72563966 @default.
• W1966403265 hasConceptScore W1966403265C86803240 @default.
• W1966403265 hasLocation W19664032651 @default.
• W1966403265 hasOpenAccess W1966403265 @default.
• W1966403265 hasPrimaryLocation W19664032651 @default.
• W1966403265 isParatext "false" @default.
• W1966403265 isRetracted "false" @default.
• W1966403265 magId "1966403265" @default.
• W1966403265 workType "article" @default.